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We have investigated the agonists that activate transfected extracellular signal-regulated kinase 8
(ERK8) in cells, and have found that the most potent activators are hydrogen peroxide, DNA alkyl-
ating and cross-linking agents and the poly (ADP-ribose) polymerase inhibitor KU-0058948. The fea-
ture shared by all these agents is that they lead to the accumulation of single strand breaks in DNA,
suggesting a role for ERK8 in the response to, or repair of, DNA single strand breaks. The DNA alkyl-
ating agent MMS also induced the disappearance of endogenous ERK8 by a proteasome-dependent
mechanism.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The most recently described member of the mitogen-activated
protein (MAP) kinase family is extracellular signal-regulated ki-
nase 8 (ERK8) [1], which is most closely related to ERK1, ERK2
and ERK5. Like these protein kinases, ERK8 possesses a signature
Thr-Glu-Tyr motif in its activation loop but, in contrast to ERK1,
2 and 5, ERK8 does not appear to require an ‘‘upstream” activating
kinase, and instead phosphorylates and activates itself [1,2]. More-
over, in contrast to ERK1 and ERK2, whose activation requires the
dual phosphorylation of the Thr as well as the Tyr of the Thr-Glu-
Tyr motif, the activity of ERK8 is determined by level of phosphor-
ylation of the Thr residue alone. The activity of transfected ERK8 is
therefore a balance between the rate at which it autophosphory-
lates this Thr and the rate at which this residue is dephosphoryl-
ated by one or more members of the PPP family of protein
serine/threonine phosphatases [2].
ERK8 has a low basal activity, but we found that its activity is
increased 5-fold or more after exposure to hydrogen peroxide
[2]. Hydrogen peroxide is a source of reactive oxygen species that
attack cellular DNA and cause single strand breaks, which
prompted us to investigate the effects of other DNA damaging
agents on the activation of ERK8. Here, we report that DNA alkyl-
ating and cross-linking agents, as well as the poly (ADP-ribose)
polymerase (PARP) inhibitor KU-0058948, which all lead to the
accumulation of single strand breaks (SSBs) in DNA, are potentchemical Societies. Published by Eactivators of ERK8. In contrast other agents that cause different
types of DNA damage failed to activate ERK8 signiﬁcantly. These
observations suggest an important role for ERK8 in the regulation
of DNA damage.
2. Materials and methods
2.1. Materials
Methyl methane sulphonate (MMS), hydroxyurea (HU) and
cisplatin were purchased from Sigma Chemical Co (Poole, UK),
N-methyl-N0-nitro-N-nitrosoguanidine (MNNG) from TCI Europe
(Boerenveldseweg, Belgium) and MG132 and Proteasome Inhibitor
I from Calbiochem (Nottingham, UK). KU-55933 [3] and
KU-0058948 [4,5] were synthesised by established methods. The
sources of other reagents and DNA constructs have been described
[2].
2.2. Antibodies
Two different antibodies were raised in sheep that both recog-
nise the phosphorylated and unphosphorylated forms of ERK8
equally well. One was raised against a glutathione S-transferase
(GST)-ERK8 fusion protein (Sheep 324B, bleed 1) and the other
against His6-ERK8 (Sheep S78B, bleeds 1, 2 and 4). The antisera
were afﬁnity puriﬁed by Kerry Burness, Division of Signal Trans-
duction Therapy, MRC Protein Phosphorylation Unit, University of
Dundee [2]. A polyclonal antibody that recognises the phosphory-
lated Thr-Glu-Tyr motifs of ERK1 and ERK2, an antibody thatlsevier B.V. All rights reserved.
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Fig. 1. The effect of DNA damaging agents on the activity and phosphorylation of
ERK8. (A) HEK293 cells were transfected with a vector encoding wild type HA-ERK8.
Thirty-six hours post-transfection, the cells were treated for 10 min with 1 mM
H2O2 or for 2 h with 2 mM MMS, or exposed to 50 J/m2 UV-C or 10 Gy c-radiation
(ionising radiation, IR) followed by incubation for 2 h at 37 C. The cells were lysed,
ERK8 was immunoprecipitated from 0.5 mg of cell extract protein and its activity
measured using myelin basic protein (MBP) as a substrate [2]. (B) The cell extracts
from (A) were immunoblotted with an antibody that recognises the phosphorylated
Thr-Glu-Tyr motifs of ERK1, ERK2 and ERK8 (pERK8), and an antibody that
recognises all forms of ERK8 equally well (ERK8). (C) The cells were transfected and
36 h later exposed to 2 mM MMS and lysed at the times indicated. ERK8 was
immunoprecipitated from the cell extracts and its activity measured as in (A).
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nases, and antibodies that recognise Chkl phosphorylated at
Ser345 and Chk2 phosphorylated at Thr68, were purchased from
Cell Signaling Technologies (Hitchin, UK). The antibody that recog-
nises the phosphorylated Thr-Pro-Tyr motif of c-Jun N-terminal ki-
nases (JNKs) was from Biosource (Invitrogen, Paisley, UK). An anti-
ubiquitin antibody was purchased from DakoCytomation (Cam-
bridgeshire, UK), an anti-ATR antibody was from Santa Cruz, and
an anti-HA antibody (clone 12CA5) from Roche (Lewes, UK).
2.3. Cell culture, transfection, stimulation and lysis
The cell lines used were maintained in a 95% air/5% CO2 atmo-
sphere at 37 C. HEK293 cells were cultured as described [2], whilst
HCT116 and ATRﬂox/- cells were cultured in McCoy’s 5A medium
according to instructions provided by the American Tissue Culture
Collection. HEK293 cells were transiently transfected with a
pCMV5 ERK8 vector that expresses haemaglutinnin (HA)-tagged
ERK8 using polyethylenimine (PEI) [2]. ATRﬂox/- cells were in-
fected with adenovirus-expressing CRE recombinase, the medium
changed after 24 h, and the cells transfected with a vector express-
ing HA-ERK8 using lipofectamine 2000. Forty-six and forty-eight
hours later the medium was changed and the cells were exposed
for 2 h to 2 mMMMS or for 10 min to hydrogen peroxide, and then
lysed. For all other experiments the cells were stimulated with
2 mMMMS, 10 lM cisplatin, 2 lMMNNG or 2 mM HU, or exposed
to 1 lM KU-0058948 for the times indicated in the ﬁgure legends.
For ionising (c)-radiation (IR), cells were exposed to a 137Cs source
at 10 Gy, whilst ultraviolet radiation was administered at 254 nm
(UV-C) using a Spectrolinker (Spectronics Corporation) at 50 J/m2.
The cells used in the present study were lysed [4], centrifuged at
13000g for 10 min at 4 C, and the supernatants (termed cell
extracts) removed, frozen and stored at 20 C until use.
2.4. Immunoprecipitation of endogenous ERK8 from cell extracts
Extracts prepared from HCT116 or HeLa cells (10 mg extract
protein) were immunoprecipitated with an anti-ERK8 antibody
coupled covalently to Protein G-Sepharose. Routinely, 3 lg of
antibody was used per mg of extract protein. Immunoprecipita-
tion was carried out for 6 h at 4 C with continuous agitation.
Following centrifugation for 2 min at 5000g, the supernatants
were discarded and the pellet washed once in lysis buffer con-
taining 0.15 M NaCl, then twice in lysis buffer alone. Samples
were denatured in SDS, subjected to SDS–PAGE, transferred to
PVDF membranes and immunoblotted using the ECL detection
system.3. Results and discussion
3.1. Phosphorylation and activation of ERK8 in response to DNA
damaging agents
We reported previously that hydrogen peroxide induced the
phosphorylation and activation of transfected ERK8 in HEK293
cells (see 1). Hydrogen peroxide is a source of reactive oxygen
species that could exert this effect in several ways, for example
by attacking cellular DNA and cause single strand breaks (SSBs)
in DNA (see 1). We therefore examined whether the DNA-akylating
agent MMS, which also leads to the accumulation of SSBs, was able
to activate ERK8. We found that MMS did indeed activate transfec-
ted ERK8 (Fig. 1A) and induced the phosphorylation of its Thr-
Glu-Tyr motif (Fig. 1A) to a similar extent to hydrogen peroxide,
although activation by MMS was slower. Activation by hydrogen
peroxide was maximal after 10 min and sustained for at least30–60 min [2]. In contrast, little activation by MMS was observed
after 30 min (results not shown) and activation only became max-
imal after 1–2 h, declining thereafter (Fig. 1C). Several other DNA-
damaging agents only activated ERK8 slightly up to 8 h of treat-
ment. These included ionising radiation that causes double-strand
breaks and UV-C that causes DNA photoproducts (Fig. 1A) and HU
(an inhibitor of ribonucleotide reductase) (data not shown).
These results described above suggested that ERK8 might be
activated speciﬁcally when SSBs in DNA accumulate. To investigate
this further, we therefore exposed the cells to MNNG, another DNA
alkylating agent, and to cisplatin, a DNA cross-linking agent, both
of which also cause SSBs, possibly in the form of single strand gaps.
These experiments showed that MNNG (Fig. 2A) and cisplatin
(Fig. 2B) were potent, but slower activators of ERK8 than MMS.
However, the activation of ERK8 attained after a 24 h exposure to
MNNG or cisplatin was much higher than the maximal activation
by MMS, which occurred after 2 h (Fig. 1C).
The compound KU-0058948 inhibits members of the poly (ADP-
ribose) polymerase (PARP) family, which includes PARPl, an en-
zyme required for the repair of single strand breaks [4]. The pro-
longed incubation of cells with KU-0058948 therefore also leads
to the accumulation of SSBs, and we found that this compound also
activated ERK8 with a time course similar to MNNG and cisplatin
(Fig. 2C).
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Fig. 2. The effect of MNNG, cisplatin and KU-0058948 on the phosphorylation of ERK8. HEK293 cells transfected as in Fig. 1A were treated with 2 mM MMS or 2 lM MNNG
(A), 2 mMMMS or 10 lM cisplatin (B) or 2 mMMMS or 1 lMKU-0058948 (C) and lysed at the times indicated. The cell extracts (60 lg protein) were immunoblotted with the
antibodies used in Fig. IB, an antibody that recognises Chk2 phosphorylated at Thr 68 (pChk2), and an antibody that recognises the phosphorylated Thr-Pro-Tyr motif of JNK
isoforms (pJNK).
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(Fig. 2) and p38 MAPK (not shown). However, although MNNG, cis-
platin and the PARP inhibitor KU-0058948 all activated ERK8 more
potently than MMS, they were much weaker activators of JNK
(Fig. 2) and p38 MAPK (results not shown). Indeed, KU-0058948
was unable to activate these MAP kinase at all under the conditions
tested (Fig. 2).pChk2 
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Fig. 3. The effect of the ATM inhibitor KU-55933 or ATR depletion on the
phosphorylation of ERK8. (A) HEK293 cells were transfected as in Fig. 1A and
36 h post-transfection incubated with (+) or without () 10 lM KU-55933, then
exposed for 2 h to 2 mM MMS and lysed. The cell extracts (60 lg) were
immunoblotted with the antibodies used in Fig. 2 and an antibody that recognises
Chkl phosphorylated at Ser 345 (pChkl). (B) HCT116 and ATRﬂox/- cells were
infected in the presence (+) or absence () of adenovirus-expressing CRE recom-
binase (Ade-CRE). Forty-eight hours post-infection the cells were transfected with a
vector expressing HA-ERK8, and after a further 24 h the cells were exposed for
10 min to 1 mM hydrogen peroxide or for 1 h to 2 mM MMS and lysed. The cell
extracts (60 lg protein) were immunoblotted as in A and with an anti-ATR antibody
(ATR).3.2. Mechanism of action of ERK8
Upon DNA damage, two signaling pathways are activated that
are important in mediating DNA damage responses and DNA re-
pair. One of these pathways leads to the activation of the Ataxia
Telangactasia Mutated (ATM) protein kinase, which then phos-
phorylates and activates the protein kinase Chk2, as well as
many other substrates. The second pathway leads to the activa-
tion of the ATM and Rad3-related kinase (ATR) which phosphor-
ylates and activates the protein kinase Chkl and other substrates.
To determine whether ERK8 is activated downstream of ATM, we
incubated cells with KU-55933, a speciﬁc ATM inhibitor [3].
These experiments showed that KU-55933 prevented the MMS-
stimulated phosphorylaton of Chk2 as expected, without affect-
ing the MMS-induced activation of ERK8 (Fig. 3A). Thus the
MMS-induced activation of ERK8 does not require the ATM-
Chk2 signaling pathway. To determine whether ERK8 was acti-
vated downstream of ATR we depleted this protein kinase from
ATRﬂox/- colon carcinoma cells [6]. The complete depletion of
ATR had no effect on the MMS or hydrogen peroxide induced
activation of ERK8 (Fig. 3B), demonstrating that the activation
of ERK8 does not require the ATR-CHK1 pathway. Taken together,
these results demonstrate that the MMS-stimulated activation of
ERK8 is not mediated by ATM-Chk2 or ATR-Chkl.
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I.V. Klevernic et al. / FEBS Letters 583 (2009) 680–684 6833.3. Prolonged treatment with MMS decreases the level of ERK8
Although the MMS-induced activation of transfected ERK8
peaked after 2 h and declined thereafter, we noticed that the de-
cline in activity did not result from dephosphorylation, but corre-
lated with the loss of the ERK8 protein, which had almost
disappeared after a 6–8 h exposure to MMS (Fig. 4A). In contrast,
the levels of ERK1 and ERK2 did not decline. The MMS-stimulated
disappearance of ERK8 did not require ERK8 activity, since the
expression of the transfected catalytically inactive ERK8[D154A]
declined in parallel (Fig. 4B). As reported previously for hydrogen
peroxide [2], MMS failed to induce the phosphorylation of
ERK8[D154A] (Fig. 4B), indicating that activation of the wild-type
ERK8 had resulted from autophosphorylation.
3.4. Studies on the expression of endogenous ERK8
The endogenous ERK8 protein has never been studied previ-
ously due to its low abundance in cells and lack of sufﬁciently sen-
sitive antibodies for its detection. To investigate whether the
disappearance of transfected ERK8 after prolonged MMS-treat-
ment was also observed with the endogenous protein, we raised
two different antibodies that were capable of immunoprecipitating
endogenous ERK8 from cell extracts. Following immunoprecipita-
tion with either antibody we immunoblotted with the S324B anti-
body (Fig. SIA) or with the S78B antibody (results not shown). In
each case an identical doublet was observed (Fig. SIA), the upper
band of the doublet co-migrating with transfected ERK8
(Fig. SIB). These results suggested that this doublet did indeed cor-
respond to the endogenous ERK8 and that the lower band, whichpERK8
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Fig. 4. Effect of MMS on the phosphorylation and expression of ERK8. (A) HEK293
cells were transfected with a vector expressing wild type HA-ERK8. Thirty-six hours
post-transfection, the cells were either exposed for 10 min (0.17 h) to 1 mM
hydrogen peroxide or to 2 mM MMS for the times indicated. Cell extracts (60 lg
protein) were immunoblotted with the antibodies used in Fig. 1B and an antibody
that recognises all forms of ERK1 and ERK2. (B) The cells were transfected with
vectors encoding either wild type (WT) HA-ERK8 or a catalytically inactive mutant
HA-ERK8[D154A]. Thirty-six hours post-transfection, the cells were exposed to
MMS and lysed at the times indicated. Cell extract protein (60 lg) was denatured in
SDS, resolved by SDS–PAGE and immunoblotted with the antibodies used in A.
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Fig. 5. Regulation of the expression of endogenous ERK8 inHCT116 cells. (A) HCT116
cells were seeded and kept for 48 h in culture medium containing 10% FBS. The cells
were lysed (Lane A) or the medium removed and either replaced with serum-free
medium and kept for 4 h before lysis (Lane B) or replaced with fresh medium
containing 10% FBS and kept for the times indicated before lysis (Lanes C–F). ERK8
was immunoprecipitated (IP) using anti-ERK8 (Lanes A–F) or control sheep IgG (IgG)
and immunoblottedwith anti-ERK8 (upper panel). Cell extracts (60 lg protein) were
immunoblotted with anti-ERKl/ERK2 (lower panel). (B) The cells were seeded and
maintained for 48 h as in (A). The culture medium (termed ‘‘old medium”) was
removed and the cells either lysed (Lane A) or incubated for 4 hwith fresh serum-free
medium (Lanes B–G). Theywere then either lysed (Lane B) or the serum-freemedium
replaced with the original ‘‘old medium” (Lanes C–G). After incubation for the times
indicated, the cells were lysed, ERK8 immunoprecipitated (IP) and immunoblotted
with anti-ERK8 (upper panel labelled IP). Non-immune IgG replaced anti-ERK8 in
control experiments (IgG). The cell extracts were also immunoblotted with antibod-
ies recognising all forms of ERK1 and ERK2 (lower panel). (C) The cells were seeded
and maintained for 48 h in culture medium containing 10% FBS. The medium was
removed and the cells either lysed (Lane A) or the ‘‘old medium” replaced with fresh
mediumwithout serum(LanesB–G). After4 h, the cellswere either lysed (LanesBand
C) or exposed to 2 mMMMS and lysed at the times speciﬁed (Lanes D–G). ERK8 was
immunoprecipitated from the cell extracts and the immunoblotted with anti-ERK8
(top panel), while 60 lg of cell extract protein was immunoblotted to detect
phospho-JNK and total ERKl/2. (D) The cells were seeded, maintained in culture for
48 h, then incubated for 2.5 h with (+) or without () 25 lM MG132 or 10 lM
Proteasome Inhibitor I and lysed (Lanes A–C). Alternatively, the ‘‘old medium” was
removed after 48 h and the cells incubated for 4 h with fresh serum-free medium to
elevate ERK8 expression before lysis (Lanes D and E). In lanes F–H the cells were
treated as for Lanes D and E except that, after 3 h in serum-free medium, they were
incubated for 1 h without () or with (+) MG132 or Proteasome Inhibitor I. The cells
were then exposed to 2 mMMMS for 6 h followed by lysis. Immunoprecipitation and
immunoblotting of ERK8was then carried out as in A and 60 lg of cell extract protein
was immunoblotted with anti-ERKl/ERK2 and anti-ubiquitin.
684 I.V. Klevernic et al. / FEBS Letters 583 (2009) 680–684was not always present (for example see Fig. 5), may arise from the
proteolytic removal of a small peptide from one end of the protein.
The identiﬁcation of this band as ERK8 was conﬁrmed by an siRNA
‘‘knock-down” experiments in HCT116 cells (Fig. SIC) and HeLa
cells (results not shown). The amount of ERK8 immunoprecipitated
from 10 mg cell extract protein was less than the amount of ERK8
present in 60 lg of cell extract prepared from transfected cells
(Fig. SIB), explaining why the endogenous ERK8 cannot be detected
by immunoblotting of cell extracts.
The level of endogenous ERK8 in HCT116 cells was extremely
low after incubation for 48 h in normal growth medium. Interest-
ingly, however, we found that the level of endogenous ERK8 rose
sharply if the ‘‘old medium” was replaced by fresh medium, reach-
ing a maximum after 4–6 h and then declining by about 50% over
the next 24 h (Fig. 5A) and to almost nothing after 48 h (results
not shown). A similar increase in ERK8 was observed when ‘‘old
medium” was replaced by fresh, serum-free medium, demonstrat-
ing that the decreased expression of ERK8 after 48 h was not
caused by the loss of a component present in foetal bovine serum
(FBS). Instead, the results suggested that a factor accumulating in
the culture medium after 48 h might be responsible for the de-
creased expression of ERK8. To test this hypothesis, we incubated
HCT116 cells for 48 h in normal medium, then removed this ‘‘old”
medium and set it aside. The cells were then cultured for 4 h in ser-
um-free medium to elevate ERK8 expression, followed by incuba-
tion once again with ‘‘old medium”. The ‘‘old medium” induced a
rapid decline in the expression of ERK8, which was essentially
complete after 15 min (Fig. 5B). These results again indicated that
a factor(s) secreted from HCT116 cells was responsible for decreas-
ing the level of expression of ERK8 after prolonged incubation in
cell culture.
3.5. MMS decreases the expression of endogenous ERK8 by a
proteasome-dependent event
To study the effect of MMS, HCT116 cells were cultured for 48 h
in normal medium, then transferred to fresh serum-free medium
for 4 h to increase the level of endogenous ERK8, before exposure
to MMS. As observed for the transfected protein (Fig. 4A), MMS in-
duced a gradual decline in the level of endogenous ERK8, hardly
any protein remaining after 6 h (Fig. 5C). Two structurally distinct
proteasome inhibitors, MG132 and Proteasome Inhibitor I, sup-
pressed the MMS-induced decline in the level of the endogenous
ERK8 protein, as well as increasing the overall extent of protein
polyubiquitination in cells as expected (Fig. 5D, lanes D–H). How-
ever, incubation with these proteasome inhibitors did not prevent
the decline in the expression of ERK8 that occurred after incuba-
tion in culture medium for 48 h (Fig. 5D, lanes A–C), and nor didit prevent the MMS-induced decrease in the expression of transfec-
ted ERK8 (results not shown)
3.6. Concluding remarks
The results presented in this paper demonstrate that the most
potent activators of ERK8 all lead to the accumulation of SSBs in
DNA by a mechanism that is independent of the activation of
ATM or ATR. These ﬁndings suggest that ERK8 may play a role in
the response to, or repair of, SSBs. It will clearly now be of great
interest to investigate whether the depletion of ERK8 from cells af-
fects cellular sensitivity to agents that cause SSBs.
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